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Seminarsthrombocytopenia (ITP) is essential since treatment decisions are complex and using platelet
count only partly explains disease burden. Since most symptoms are only experienced
subjectively and are seldom captured during clinician-based evaluations, using self-report is
crucial for early symptom detection. However, capturing the patient’s illness experience
necessitates using well-developed and validated instruments. This article provides insight on
the importance of using PROs in ITP, summarizes the methodological steps to develop PRO
instruments, and discusses challenges related to integrating PROs into research and clinical
practice.
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mmune thrombocytopenia (ITP) affects between
2–6 people per 100,000 per year.1 While the
disease in children generally has a sudden onset
but a good prognosis, ITP in adults often presents
gradually but tends to be chronic in nature. Choos-
ing the right therapy at the right time is the most
challenging task for clinicians. Treatment side effects
can be substantial, and are often perceivedblished by Elsevier Inc.
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Open access under CC BY-NC-ND license.by patients as worse than the symptoms of the
disease.2 Traditionally, the assessment of a patient’s
response to the chosen treatment has been exclu-
sively made by clinicians based on platelet count and
clinical bleeding.3 However, given that many
patients with very low platelet counts do not bleed,
it is emphasized that treatment choice should rely
more on symptoms,4 underscoring the importance
of incorporating the patient’s perspective by using
patient-reported outcomes (PROs). A PRO is any
report of the status of a patient’s health condition
that comes directly from the patient, without inter-
pretation of the patient’s response by a clinician or
anyone else. Examples include quality of life (QoL),
symptom experience, treatment satisfaction, and
adherence.5
The importance of PROs in drug development
is currently acknowledged worldwide, with the
requirement that the PRO instruments are created
and validated according to well-described stand-
ards outlined in the US Food and Drug Adminis-
tration (FDA) guidance and the reflection paper
on the measures of health-related QoL of the
European Medicines Agency.5,6 This article
summarizes the advantages of using PROs in ITP,
provides insight into the different metho-
dological steps involved in developing or modify-
ing instruments, and provides examples of how
they can be incorporated into research and clin-
ical practice.p S39–S42 S39
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First, PROs facilitate better understanding of the
impact of the disease and treatment on the patients’
life. Assessing the patient’s perspective may reveal
valuable information that would be missed when
relying exclusively on clinician report.7 For example,
current American Society of Hematology treatment
guidelines focus on the medical side effects of
corticosteroids, including hyperglycemia and osteo-
porosis, whereas weight gain, mood swings, and
puffy face are most bothersome to patients.8 Second,
the patients’ perspective might provide unique
insights on treatment effectiveness. Directly asking
the patient about adherence in the situation of non-
response to corticosteroids, for example, might
facilitate a deeper understanding why the drugs
are not working. Third, PROs can be relevant in
decision-making processes. Two drugs can have
similar effectiveness but different side effect profiles.
In particular, patients report higher treatment-bother
with corticosteroids than with other ITP therapies.9
Patients’ preferences might therefore guide treat-
ment choice.
Because of these recognized values, the European
Hematology Association Scientific Working Group
‘‘Quality of Life and Symptoms’’ developed the
‘‘Patient-Reported Outcomes in Hematology’’ guide-
lines, which cover conceptual, methodological, and
practical issues surrounding PRO measurement.
They provide an overview of existing instruments,
and describe state-of-the art studies incorporating
PROs, of which some key insights are discussed
below.10WHAT CONSTITUTES A GOOD PRO?
Developing a PRO is not a ‘‘do it yourself’’
project. It is labor-intensive, necessitating meticu-
lous methodology, and requires a collaborative
team of clinicians, scientists, statisticians, and
patients. Excellent methodological guidance is
offered by the article series published in ‘‘Value in
Health.’’11 Before developing a new PRO, clinicians
should consider using existing ones. Electronic
databases, such as PROQOLID and PROMIS, offer
quick and comprehensive overviews of existing
instruments. So far, however, instruments captur-
ing the patient’s experience of ITP almost exclu-
sively focus on QoL, often applying generic
instruments such as the Short Form-36 and the
EQ-5D in adults, and the PedsQL and KINDL in
children.10 Three disease-specific QoL measures are
also available: the ITP-patient administered ques-
tionnaire for adults, the Kids’ ITP Tool, and the ITP-
Quality of Life for children.12If a PRO instrument is available, each clinician
should answer five key methodological questions5,11
before adopting it in research or practice.1. Does the instrument provide a conceptual
definition?
Several PRO instruments are published that do
not describe what the instrument aims to measure,
or do not provide the conceptual framework that is
underpinning the items. One should check that what
you are trying to measure fits well with the concept
and items outlined in existing PRO instruments. For
example, if you would like to understand the impact
of ITP on a person’s social and professional function-
ing you should check whether the PRO you are
considering addresses these issues. If that is not the
case, the search for a more appropriate instrument
should continue.2. For which patient population was the PRO
instrument developed?
Instead of hastily choosing a self-report instru-
ment off the shelf, one should carefully look at the
sample characteristics: for whom was the question-
naire designed? Are these patients similar to the
study population one has in mind? Even if the
concept measured is the same, a PRO instrument
measuring side effects of immunosuppressive drugs
in transplantation might not be applicable to
patients taking immunosuppressive drugs for rheu-
matic conditions. Also, will subjects be able to
complete the questionnaire? Think of vision prob-
lems, cognitive impairments, or literacy levels. If
questionnaires are designed in a different language,
culturally sensitive translations, following rigorous
protocols are mandatory, to make sure items and
instructions are clear to patients with a different
geographical or cultural background.3. Was there sufficient patient input in the
PRO instrument development process?
Strictly speaking, if no patients were involved in
the development process, it is not really a PRO
instrument. Patient involvement is recommended at
three possible occasions.5 First, if no conceptual
definition exists, qualitative interviews with the
patient group of interest, are helpful to understand
how, for example, patients conceptualize side
effects of pharmacological treatment (eg, patients
might talk about frequency of occurrence, distress
experienced and impact on their daily functioning as
dimensions of the concept ‘‘side effects’’). Also,
interviewing patients allows to identifying the symp-
toms which they deem to be important. Second,
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items in line with the conceptual definition. An
instrument on side effect experience, for example,
would not be a good instrument if it only assesses
the occurrence of side effects but not the severity, or
if the list of side effects measured is incomplete.
When developing items, it is recommended that
instrument developers stay as close as possible to
the patients’ wordings. Patients will for instance talk
about wind or gas and not flatulence, or hair growth
and not hirsutism. Finally, once the instrument is
drafted, the appropriateness of recall period and
response options, as well as the clarity of instruc-
tions and items needs to be evaluated with patients
(also called cognitive debriefings).4. Are the instrument’s reliability and validity
well established?
Validity and reliability testing is an ongoing proc-
ess that involves many different test procedures that
need to be conducted in the study population of
interest. When selecting an instrument, one should
ask if and to what extent it has been validated in a
population that is similar to the one of interest. If
treatment-related improvement of PROs is a primary
research goal, it is also good to know if the instru-
ment is responsive to change. Many types of validity
(eg, content, concurrent, construct) and reliability
(eg, internal consistency, test–retest) can be tested.
The interested reader can find an overview of
terminology related to psychometric testing in the
paper of Kimberlin and Winterstein.135. How to interpret the collected PRO data?
Interpretability means the degree to which one
can assign easily understood meaning to an instru-
ment’s quantitative score, and represents one of the
most complicated challenges in PRO measure-
ment.14 Optimally, test developers give clear infor-
mation about scoring and interpretation and if not
there exists evidence guiding scoring interpreta-
tion.15 Even more important is the distinction
between ‘‘statistically significant’’ and ‘‘clinically
relevant’’ differences. For instance, differences in
QoL between stable chronic ITP patients taking
romiplostim therapy and those with no treatment
might be statistically significant, but an individual
patient might not actually feel a ‘‘2 points scale
difference’’ in daily life.INTEGRATING PROs IN CLINICAL RESEARCH
AND PRACTICE
At present, the systematic use of PRO instruments
in clinical care and research is rare, because of bothclinician and patient factors. Although most clini-
cians agree that PROs are important to capture the
patient’s experience, their integration in clinical
workflows is thought to be burdensome, labor-
intense, or will increase administrative costs. How-
ever, PRO instruments can be successfully imple-
mented in clinical processes by using thorough
planning, training of personnel, and pilot-testing.
They can present clinicians with real-time informa-
tion that are relevant for patient communication,
decision-making, and interdisciplinary collaboration.
There is also a concern about patients’ willingness
and ability to fill out questionnaires. In particular,
the longitudinal use of PROs decreases patients’
motivation to engage actively, especially if they do
not get adequate feedback. The easier to complete
and interpret, and the more relevant the PRO
assessed, the higher the likelihood that both clini-
cians and patients will benefit of it. As a future trend,
several institutions facilitate real-time electronic PRO
(e-PRO) symptom reporting and combine them with
electronic health records.16 Features of these e-PRO
reporting systems include simple interfaces for
patients, automated reminders, clear reports for
clinicians that illustrate longitudinal illness trajecto-
ries, and real-time alerts when alarming symptoms
are reported. The routine use of e-PRO data in the
ITP setting could create a rich data source to enable
understanding of the patient experience and link
this to clinical and economic outcomes.CONCLUSIONS
The use of PROs adds to the understanding how
patients are affected by ITP and of the treatment and
health care provided. PROs can help in deciding
whether to modify specific treatment elements such
as medications, consultant care, patient education,
or support services. The purpose of including PROs
in clinical studies is to understand the patient’s
perspective on what is gained or lost from treatment.
Optimally, clinical practice and research should
combine objective diagnostics with PRO instru-
ments. This approach will contribute to patient care
quality by detecting health changes and nascent
problems undetectable via clinical observations,
leading to early treatment and hence to improved
patient outcomes.
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